File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Erlotinib as salvage treatment after failure to first-line Gefitinib in non-small cell lung cancer

TitleErlotinib as salvage treatment after failure to first-line Gefitinib in non-small cell lung cancer
Authors
KeywordsAsians
Disease control rate
Epidermal growth factor receptor tyrosine kinase inhibitors
Erlotinib
Gefitinib
Non-small cell lung cancer
Issue Date2010
PublisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280
Citation
Cancer Chemotherapy And Pharmacology, 2010, v. 65 n. 6, p. 1023-1028 How to Cite?
Abstract
Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer (NSCLC). Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been recently shown to be effective as a first-line treatment in Asian patients with advanced NSCLC, especially for those with favourable clinical features such as female, non-smoker and adenocarcinoma. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment. The purpose of this study is to evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of gefitinib. Method Retrospective review of NSCLC patients with favourable clinical features who received gefitinib as firstline treatment and subsequent salvage treatment with erlotinib. Results A total of 21 patients with NSCLC were included in the study. Among them, 18 (85.7%) patients had disease control with gefitinib and 12 (57.1%) patients with salvage erlotinib. There was an association between the disease control with gefitinib and erlotinib (p = 0.031). The disease control rate of erlotinib was independent of the chemotherapy use between the two EGFR-TKIs. Conclusion For NSCLC patients with favourable clinical features, erlotinib was effective in those who had prior disease control with first-line gefitinib. © Springer-Verlag 2009.
Persistent Identifierhttp://hdl.handle.net/10722/123997
ISSN
2013 Impact Factor: 2.571
PubMed Central ID
ISI Accession Number ID
References

 

Author Affiliations
  1. Centro Hospital Conde de Sao Januario
  2. The University of Hong Kong
DC FieldValueLanguage
dc.contributor.authorWong, MKen_HK
dc.contributor.authorLo, AIen_HK
dc.contributor.authorLam, Ben_HK
dc.contributor.authorLam, WKen_HK
dc.contributor.authorIp, MSen_HK
dc.contributor.authorHo, JCen_HK
dc.date.accessioned2010-10-18T06:18:55Z-
dc.date.available2010-10-18T06:18:55Z-
dc.date.issued2010en_HK
dc.identifier.citationCancer Chemotherapy And Pharmacology, 2010, v. 65 n. 6, p. 1023-1028en_HK
dc.identifier.issn0344-5704en_HK
dc.identifier.urihttp://hdl.handle.net/10722/123997-
dc.description.abstractPurpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer (NSCLC). Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been recently shown to be effective as a first-line treatment in Asian patients with advanced NSCLC, especially for those with favourable clinical features such as female, non-smoker and adenocarcinoma. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment. The purpose of this study is to evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of gefitinib. Method Retrospective review of NSCLC patients with favourable clinical features who received gefitinib as firstline treatment and subsequent salvage treatment with erlotinib. Results A total of 21 patients with NSCLC were included in the study. Among them, 18 (85.7%) patients had disease control with gefitinib and 12 (57.1%) patients with salvage erlotinib. There was an association between the disease control with gefitinib and erlotinib (p = 0.031). The disease control rate of erlotinib was independent of the chemotherapy use between the two EGFR-TKIs. Conclusion For NSCLC patients with favourable clinical features, erlotinib was effective in those who had prior disease control with first-line gefitinib. © Springer-Verlag 2009.en_HK
dc.languageeng-
dc.publisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280en_HK
dc.relation.ispartofCancer Chemotherapy and Pharmacologyen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsSpringer-Verlagen_HK
dc.subjectAsiansen_HK
dc.subjectDisease control rateen_HK
dc.subjectEpidermal growth factor receptor tyrosine kinase inhibitorsen_HK
dc.subjectErlotiniben_HK
dc.subjectGefitiniben_HK
dc.subjectNon-small cell lung canceren_HK
dc.subject.meshAged-
dc.subject.meshCarcinoma, Non-Small-Cell Lung - drug therapy-
dc.subject.meshLung Neoplasms - drug therapy-
dc.subject.meshQuinazolines - therapeutic use-
dc.subject.meshSalvage Therapy - methods-
dc.titleErlotinib as salvage treatment after failure to first-line Gefitinib in non-small cell lung canceren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0344-5704&volume=65&issue=6&spage=1023&epage=1028&date=2010&atitle=Erlotinib+as+salvage+treatment+after+failure+to+first-line+gefitinib+in+non-small+cell+lung+cancer-
dc.identifier.emailIp, MS:msmip@hku.hken_HK
dc.identifier.emailHo, JC:jhocm@hku.hken_HK
dc.identifier.authorityIp, MS=rp00347en_HK
dc.identifier.authorityHo, JC=rp00258en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1007/s00280-009-1107-5en_HK
dc.identifier.pmid19680652-
dc.identifier.pmcidPMC2946542-
dc.identifier.scopuseid_2-s2.0-77951895524en_HK
dc.identifier.hkuros172598-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77951895524&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume65en_HK
dc.identifier.issue6en_HK
dc.identifier.spage1023en_HK
dc.identifier.epage1028en_HK
dc.identifier.eissn1432-0843en_HK
dc.identifier.isiWOS:000275632400003-
dc.publisher.placeGermanyen_HK
dc.description.otherSpringer Open Choice, 01 Dec 2010-
dc.identifier.scopusauthoridWong, MK=23480818200en_HK
dc.identifier.scopusauthoridLo, AI=31767490300en_HK
dc.identifier.scopusauthoridLam, B=9246012800en_HK
dc.identifier.scopusauthoridLam, WK=35934675100en_HK
dc.identifier.scopusauthoridIp, MS=7102423259en_HK
dc.identifier.scopusauthoridHo, JC=7402649981en_HK
dc.identifier.citeulike5541820-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats